Levocabastine (trade name Livostin) is a selective second-generation H1
receptor antagonists which was discovered at Janssen Pharmaceutica in 1979.
Jun 11, 2012 ... LIVOSTIN™ 0.05% (levocabastine hydrochloride ophthalmic suspension) is a
selective histamine H1-receptor antagonist for topical ophthalmic ...
Physician reviewed levocabastine ophthalmic patient information - includes
levocabastine ophthalmic description, dosage and directions.
Learn about the potential side effects of levocabastine ophthalmic. Includes
common and rare side effects information for consumers and healthcare ...
Jun 13, 2005 ... Levocabastine is a selective second-generation H1-receptor antagonist used for
allergic conjunctivitis. Levocabastine was discovered at ...
LIVOSTIN™ 0.05% (levocabastine hydrochloride ophthalmic suspension) is a
selective histamine H1-receptor antagonist for topical ophthalmic use. Each mL ...
Jul 1, 1996 ... Livostin (Janssen-Cilag) 0.5 mg/mL as nasal spray and eye drops. Indication:
allergic rhinitis/conjunctivitis. Levocabastine is a H1 receptor ...
Sigma-Aldrich offers Sigma-L3042, Levocabastine hydrochloride for your
research needs. Find product specific information including CAS, MSDS,
protocols and ...
GSK Clinical Study Register - Studies filtered by compound fluticasone furoate/
Sep 19, 2013 ... Subjects will receive repeat doses of intra-nasal levocabastine for 7 days in each
period and the duration of the study will be about 13 weeks.